Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.9K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.9K
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

7.8K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.8K
Hormonal Regulation01:33

Hormonal Regulation

30.4K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
30.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Procedural Framework for Combined Mechanical Thrombectomy and Continuous rtPA Thrombolysis in the Recanalization of Deep Cerebral Venous Thrombosis in a Pediatric Patient.

Clinical neuroradiology·2026
Same author

Differentiating aetiologies in perimesencephalic SAH: clinical insights into basilar artery perforator aneurysms.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Increased free interstitial fluid in the normal appearing brain in idiopathic normal pressure and post-hemorrhagic hydrocephalus despite unchanged choroid plexus size.

Neuroradiology·2026
Same author

Clinical evidence standards for high-risk endovascular devices in ischemic stroke: a European multisociety consensus.

Journal of neurointerventional surgery·2026
Same author

Comparison of volume- and surface-based magnetic resonance imaging morphometry algorithms in the detection of focal cortical dysplasia.

Epilepsia·2026
Same author

Irregularly Shaped Microplastic Particles Compromise the Integrity of the Glomerular Filtration Barrier of the Kidney.

Kidney360·2026

Related Experiment Video

Updated: May 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

Natriuretic peptides buffer renin-dependent hypertension.

Theo Demerath1, Janina Staffel1, Andrea Schreiber1

  • 1Institute of Physiology, University of Regensburg, Regensburg, Germany.

American Journal of Physiology. Renal Physiology
|April 11, 2014
PubMed
Summary

Natriuretic peptides, like atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP), buffer renovascular hypertension through mechanisms independent of the renin system, primarily via vasodilation.

Keywords:
B-type natriuretic peptideatrial natriuretic peptideguanylyl cyclase Ahypertensionrenin

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

5.1K

Related Experiment Videos

Last Updated: May 1, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K
Nitropeptide Profiling and Identification Illustrated by Angiotensin II
07:31

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

5.1K

Area of Science:

  • Cardiovascular Physiology
  • Renal Physiology
  • Endocrinology

Background:

  • The renin-angiotensin-aldosterone system and natriuretic peptides counterbalance arterial blood pressure.
  • Elevated plasma renin concentration (PRC) and atrial natriuretic peptide (ANP) occur in renovascular hypertension.
  • ANP normally suppresses renin release, suggesting a potential role in buffering this condition.

Purpose of the Study:

  • To investigate if high ANP levels attenuate PRC increase during renal hypoperfusion.
  • To determine the role of ANP in buffering renovascular hypertension.
  • To explore the mechanisms by which natriuretic peptides affect blood pressure regulation.

Main Methods:

  • Utilized ANP knockout (ANP(-/-)) mice and wild-type (ANP(+/+)) controls.
  • Induced renovascular hypertension using unilateral renal artery stenosis (2-kidney, 1-clip).
  • Measured blood pressure, plasma renin concentration (PRC), and plasma B-type natriuretic peptide (BNP) levels. Examined guanylyl cyclase A (GC-A) knockout mice and performed isolated perfused kidney experiments.

Main Results:

  • ANP(-/-) mice exhibited hypertension and reduced PRC under control conditions.
  • Renal artery stenosis increased blood pressure and PRC similarly in both ANP genotypes.
  • Plasma BNP levels increased in ANP(-/-) mice post-stenosis, suggesting compensation.
  • GC-A knockout mice showed augmented renovascular hypertension with lower PRC.
  • Isolated kidneys showed ANP and BNP induced vasodilation and attenuated angiotensin II-mediated vasoconstriction.

Conclusions:

  • Natriuretic peptides buffer renovascular hypertension through renin-independent mechanisms.
  • Vasodilation is a key renin-independent effect of natriuretic peptides in buffering hypertension.
  • BNP may compensate for ANP deficiency in renovascular hypertension.
  • Guanylyl cyclase A signaling is crucial for the blood pressure-buffering effects of natriuretic peptides.